(November 18, 2020, 2:02 PM EST) -- TRENTON, N.J. — Efforts by Dr. Reddy’s Laboratories Inc. (DRL) to develop and market a generic form of the breast cancer treatment drug “Ibrance” represent patent infringement, Pfizer Inc. asserts in a Nov. 13 complaint filed in New Jersey federal court (Pfizer Inc. v. Dr. Reddy’s Laboratories Inc., No. 20-16117, D. N.J.)....